drugset

drugset / Trial / NCT01986218

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors

NCT01986218 ↗

Phase 1 Terminated 36 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of this study is to evaluate the safety and effectiveness of daily doses of BMS-986115 in subjects with advanced solid tumors

Timeline

Start: 2013-11
Primary completion: 2016-03
Completion: 2016-03

Outcome

Outcome not reported

Stopped (Business): “(Non-safety reason, business objectives have changed)”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	varegacestat	Small molecule	—	—

Indications